DLBCL | Clinical

Roundtable Discussion: Ansell Discusses the Importance of New and Emerging Approaches in DLBCL

June 22, 2022

During a Targeted Oncology case-based roundtable event, Stephen Ansell, MD, PhD, discussed the options for third-line therapy for relapsed/refractory diffuse large B-cell lymphoma.

Considering Alternatives to CAR T-Cell Therapy for Primary Refractory DLBCL

June 20, 2022

During a live virtual event, Jakub Svoboda, MD, discussed with participants the choice of therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who would not receive stem cell transplant or chimeric antigen receptor therapy.

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

June 15, 2022

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

Part 2: Selecting a Non-CAR T-Cell Treatment in Third-Line R/R DLBCL

June 06, 2022

During a live virtual event, Jason Westin, MD, discussed with participants the choice of third-line treatment for relapsed/refractory diffuse large B-cell lymphoma for a patient who declines chimeric antigen receptor T-cell therapy.

Tafasitamab Plus Lenalidomide Bests Standard Treatments in Key High-Risk R/R DLBCL Subgroups

June 06, 2022

According to Grzegorz S. Nowakowski, MD, results from a subgroup analysis of the observational RE-MIND study may aid in contextualizing therapy options for treating patients with relapsed or refractory diffuse large B-cell lymphoma.

First-Line Epcoritamab Demonstrates Manageable Safety and Response in Patients With High-Risk DLBCL

June 04, 2022

In the EPCORE NHL-2 trial , epcoritamab therapy was manageable and achieved high rates of response in patients with high-risk diffuse large B-cell lymphoma.

Roundtable Discussion: Budde Focuses on the Factors Affecting Treatment Decisions in B-cell Lymphoma

June 04, 2022

During a Targeted Oncology case-based event, Elizabeth Budde, MD, PhD, discussed with participants the case of a patient with relapsed/refractory diffuse large B-cell lymphoma who was not eligible for stem cell transplant and declined chimeric antigen receptor T-cell therapy.